Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Acute Care Syndromic Testing Market Poised To Hit $8.3 Billion By 2030 With A 12.5% CAGR
The acute care syndromic testing market has seen rapid growth in recent years. This market is projected to expand from $4.59 billion in 2025 to $5.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.8%. Historically, the expansion of this market can be attributed to the demand for emergency infection diagnosis, the enlargement of hospital intensive care units, initiatives focused on outbreak preparedness, the increasing adoption of molecular diagnostics, and the streamlining of critical care workflows.
The acute care syndromic testing market is anticipated to experience significant expansion in the next few years, with its size projected to reach $8.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. This growth during the forecast period is attributed to several factors including AI-enabled syndromic panels, the expansion of emergency testing, the implementation of antimicrobial stewardship programs, the development of point-of-care molecular systems, and a heightened focus on pandemic preparedness. Noteworthy trends for the same period encompass rapid multiplex pathogen detection, the integration of molecular testing in emergency departments, the availability of single-sample multi-disease panels, advancements in faster clinical decision support, and a reduction in diagnostic turnaround time.
Get A Free Sample Report With In-Depth Market Insights:
Acute Care Syndromic Testing Market Growth Factors: What’s Supporting Expansion?
The increasing prevalence of infectious diseases is projected to drive the acute care syndromic testing market forward. These illnesses are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites and can spread among people, animals, or from the environment. The rising incidence of infectious diseases is influenced by factors like population growth, urbanization, global travel, antimicrobial resistance, and climate change, thereby escalating the demand for effective prevention and treatment. Acute care syndromic testing is utilized in infectious diseases for the rapid identification of pathogens and co-infections via multiplex molecular diagnostics, enabling precise treatment decisions. For instance, in February 2024, according to the Health Security Agency, a UK-based government agency, in week 4 of 2024, the influenza positivity rate saw an increase to 16.6% from 14.0% in the preceding week. Consultations for influenza-like illness (ILI) also climbed to 9.8 per 100,000 people, up from 7.5 per 100,000 in the week prior. Additionally, influenza hospitalizations rose to 7.63 per 100,000, an increase from 5.12 per 100,000 the week before. Thus, the growing occurrence of infectious diseases is a key driver for the acute care syndromic testing market.
Acute Care Syndromic Testing Market Segment Landscape: Which Areas Lead Development?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
Acute Care Syndromic Testing Market Industry Trends: What’s Reshaping Demand?
Companies active in the acute care syndromic testing market are increasingly concentrating on technological progress, specifically multiplex real-time polymerase chain reaction (PCR) technology, to elevate diagnostic accuracy, facilitate quick pathogen detection, optimize laboratory workflows, shorten turnaround times, and enhance patient outcomes through accurate and prompt treatment. This advanced molecular diagnostic technique, multiplex real-time PCR, enables the concurrent detection and quantification of numerous pathogens or genetic targets within a single PCR reaction, thereby boosting the efficiency and precision of disease diagnosis. For example, in April 2023, QIAGEN N.V., a Netherlands-based biotechnology research company, introduced its QIAstat-Dx syndromic testing solution in Japan. This solution features a SARS-CoV-2 respiratory panel designed to detect over 20 pathogens from a single sample. By employing multiplex real-time PCR technology, it yields rapid results with significantly less labor compared to individual PCR assays. The system is accessible in over 100 countries, consequently broadening the global reach of syndromic testing.
Acute Care Syndromic Testing Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
View The Full Acute Care Syndromic Testing Market Report:
Acute Care Syndromic Testing Market Geographic Distribution And Regional Opportunities
North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
